1. Indonesia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
PT Kimia Farma (Persero) Tbk Class B

PT Kimia Farma (Persero) Tbk Class B

IIDX:KAEF
370.00
IDR
+4.00
(+1.09%)
2.34TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
782.87
814.01
875.11
1,046.36
1,103.26
1,523.09
1,692.57
1,801.62
2,315.02
1,660.2
1,774.9
1,785.48
1,656.91
- -
Basic EPS, GAAP
38.63
46.08
47.07
48.15
58.84
88.51
-2.29
3.18
54.42
-34.25
-353.14
-151.31
-60.17
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
5.54
9.7
8.45
8.96
9.63
32.91
14.98
- -
0.13
1.62
- -
0.01
- -
- -
Book Value per Share
266.45
338.68
365.59
399.88
578.26
718.72
1,303.91
1,259.16
1,043.79
1,036.48
572.22
412.01
314.81
316.66
Tangible Book Value per Share
265.84
338.1
364.58
398.91
576.37
681.78
1,265.54
1,220.48
1,008.86
999.41
535.48
392.12
296.4
298.48
Basic Weighted Avg Shares
5,554
5,554
5,554
5,554
5,554
5,554
5,554
5,554
5,554
5,561
5,562
5,567
5,567
5,567
Sales/Revenue/Turnover
4,348,074
4,521,024
4,860,371
5,811,503
6,127,479
8,459,247
9,400,535
10,006,173
12,857,627
9,232,676
9,871,842
9,938,958
9,223,328
- -
Operating Margin (%)
6.74
7.4
6.9
7.23
7.72
9.97
4.05
6.15
7.91
5
-16.86
-8.44
-1.86
- -
Depreciation Expense
17,748
28,548
27,793
30,592
37,429
58,456
101,979
150,167
228,147
207,847
354,448
413,949
412,839
- -
Net Income, GAAP
214,549
255,931
261,426
267,414
326,786
491,566
-12,724
17,639
302,274
-190,473
-1,964,157
-842,272
-334,959
- -
Effective Tax Rate (%)
24.1
25.05
25.18
29.09
26.24
29.16
58.53
72.16
26.22
- -
- -
- -
- -
- -
Profit Margin (%)
4.93
5.66
5.38
4.6
5.33
5.81
-0.14
0.18
2.35
-2.06
-19.9
-8.47
-3.63
- -
Working Capital
1,064,491
1,185,619
1,008,298
1,210,529
1,873,363
1,632,166
-47,353
-693,838
-730,791
-511,461
-4,930,638
-4,111,306
-3,080,836
157,192
LT Debt
1,873
203,094
2,190
377,714
1,095,838
1,867,146
2,524,260
2,593,487
3,253,077
1,705,008
778,897
2,724,639
3,432,114
6,410,417
Total Equity
1,496,001
1,902,964
2,056,560
2,271,407
3,273,911
4,146,258
7,412,927
7,105,672
5,889,424
8,002,756
4,778,240
3,428,809
2,735,649
2,789,726
Return on Invested Capital (%)
14.45
14.39
12.5
11.41
9.11
9.16
1.68
1.19
5.04
- -
- -
- -
- -
- -
Return on Capital (%)
14.64
14.46
12.31
11.16
8.94
8.38
1.34
1.18
5.3
- -
- -
- -
- -
- -
Return on Common Equity (%)
14.76
15.23
13.37
12.58
12.03
13.65
-0.23
0.25
4.73
-3.3
-43.97
-30.79
-16.56
- -

Capital Structure

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,546,705
2,284,019
671,008
LT Borrowings
3,384,003
4,421,671
6,315,472
LT Finance Leases
48,112
97,481
94,945
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5,567
5,567
5,567
Market Capitalization
2,866,793
2,571,764
2,337,968

Working Capital

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,979,719
4,316,463
4,767,564
Cash, Cash Equivalents & STI
377,089
426,622
445,472
Accounts Receivable, Net
1,104,554
1,118,501
1,503,177
Inventories
1,286,207
1,541,995
1,441,270
Total Current Liabilities
7,060,554
6,091,613
4,610,372
Payables & Accruals
- -
- -
- -
ST Debt
3,546,705
2,284,019
671,008
Deferred Revenue
- -
- -
- -

Growth Rates

IDR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.59%
-14%
-20.22%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
199.82%
452.9%
-60.23%
Sales/Revenue/Turnover
8.13%
0.14%
-7.2%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,535,779
2,677,917
2,650,569
2,074,694
9,938,958
2025
2,168,208
2,201,141
- -
2,215,117
9,223,328
2026
2,030,649
2,671,041
- -
- -
- -

Quarterly Earnings Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-18.47
-22.3
-35.04
-75.53
-151.31
2025
-18.36
1.29
- -
-27.89
-60.17
2026
13.37
-11.52
- -
- -
- -

Quarterly Dividends Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
0.01
- -
0.01
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Djagad Prakasa Dwialam
Full Time Employees
9,838
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Jl. Veteran No.9 Jakarta JK Indonesia 10110
IPO Date
Jul 4, 2001
Website
kimiafarma.co.id
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
PT Kimia Farma (Persero) Tbk PT Kimia Farma (Persero) Tbk (KAEF.JK) operates as an integrated healthcare company in Indonesia, engaging in the manufacturing, marketing, research and development, distribution, retail, and international trade of pharmaceutical and chemical products. Founded in 1817 by the Dutch East Indies Government as the nation's first pharmaceutical enterprise and headquartered in Jakarta, the company produces and sells a comprehensive range of items including generic, ethical, licensed and narcotic medicines; over-the-counter and herbal medicines; active pharmaceutical ingredients and raw materials; cosmetics and personal care products; medical devices and rapid diagnostic test kits; quinine salts and derivatives; health foods and effervescent tablets; castor oil and edible oils; radiopharmaceuticals; antiretrovirals; betalactam and cephalosporin antibiotics; and various forms such as tablets, capsules, syrups, suspensions, injections, creams, ointments, and antiseptics. Its six primary business segments encompass industry with 10 manufacturing factories; national distribution centers serving pharmacies, hospitals, and medical centers; retail through 1,234 Kimia Farma pharmacy outlets, 419 health clinics, 72 clinical laboratories, 8 optics stores, and 3 beauty clinics; trading; and exports to Asia, Europe, Australia, Africa, and the United States. Recent developments include a capital injection from the Indonesia Investment Authority and Silk Road Fund into PT Kimia Farma Tbk and its subsidiary PT Kimia Farma Apotek in 2025 to support expansion opportunities; divestment of stakes in PT Asuransi Jiwa Inhealth Indonesia alongside PT Bank Mandiri (Persero) Tbk in February 2024; and ongoing revenue growth to Rp7.9 trillion as of September 2024 amid operational enhancements in its integrated business chain. The company, listed on the Indonesia Stock Exchange since its IPO in July 2001, maintains subsidiaries such as PT Sinkona Indonesia Lestari for quinine production and continues to optimize assets through good corporate governance and professional human resources.